Clinical Trial Update: Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine [Phase 1]

View source ↗

Summary

Phase 1 study evaluating conditioning with cyclophosphamide or denileukin diftitox followed by expansion of the patient’s own T cells for HER2-overexpressing me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Epithelial Ovarian Cancer
• Non-small Cell Lung Cancer
• Ovarian Germ Cell Tumor

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Denileukin diftitox (denileukin diftitox)

Snippet

Sponsor: University of Washington | Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer | Phase 1 | Status: COMPLETED